Why Korean Sunscreen Is Getting Harder to Buy in the US
A Korean sunscreen can be sold legally in Korea yet fail to meet US sunscreen requirements. The FDA regulates sunscreen as an over-the-counter drug; Korea regulates it as a functional cosmetic. The June 2026 addition of bemotrizinol to the US monograph widened the available filter list, but did not authorize every finished Korean formula for US sale.
| United States (FDA) | South Korea (MFDS) | |
|---|---|---|
| Legal category | OTC drug (M020 sunscreen monograph) | 기능성화장품 (functional cosmetic) |
| UV-filter list entries | 17, after the June 2026 addition | 32, after the March 18, 2026 amendment |
| Most recent new filter | Bemotrizinol, June 2026 — first monograph addition since 1999 | Phenylene bis-diphenyltriazine, added March 2026 |
| Annual OTC facility fee (2024) | $22,777–$34,166 per manufacturing site | Not applicable — cosmetics aren't drug-registered |
US monograph count reflects the June 2026 addition; the Korean list follows MFDS Notice 2026-19. OMUFA amounts are explicitly fiscal-year 2024 examples.
Why the US treats sunscreen as a drug
A lot of the "Korean sunscreen ban" framing circulating on social media conflates two separate US rules. MoCRA (the Modernization of Cosmetics Regulation Act, 2022) governs facility registration and product listing for cosmetics generally — it isn't what keeps Korean sunscreen off shelves. The actual barrier is that the FDA classifies sunscreen specifically as an over-the-counter drug, regulated under the M020 monograph, rather than as a cosmetic. That single classification decision is what triggers everything else: a closed list of approved active ingredients, drug-manufacturing facility registration, and per-product SPF testing.
South Korea's Ministry of Food and Drug Safety (MFDS) regulates sunscreen as a functional cosmetic. A product must meet the requirements of the market where it is sold; Korean compliance does not establish US compliance. The two systems differ in permitted filters, labeling and the regulatory route for the finished product.
The Filter Gap: What Bemotrizinol's Approval Actually Changes
A filter that is permitted abroad does not automatically enter the US OTC sunscreen monograph. FDA evaluates the evidence submitted for that ingredient. Review time and cost vary; a historical delay is not a fixed waiting period for every new filter.
In June 2026, FDA added bemotrizinol to the sunscreen monograph at concentrations up to 6%. This expands the monograph toolkit, while other filters used in Korean formulas remain outside it. FDA’s sunscreen regulatory Q&A identifies the applicable final order.
The final order also carries an 18-month exclusivity provision for DSM Nutritional Products LLC and its qualifying licensees, assignees or successors. A finished sunscreen still has to meet US drug requirements. Our Korean and US sunscreen overview explains the distinction between an ingredient entering the monograph and a product reaching the market.
The Paperwork Bill Korean Exporters Are Actually Paying
Qualifying OTC monograph drug facilities pay annual OMUFA fees. For fiscal year 2024, FDA set $34,166 for an MDF facility and $22,777 for a CMO facility. These are historical facility fees, not a current per-product registration price. FDA’s OMUFA page provides the applicable fiscal-year notices.
For a small or mid-size Korean indie brand, that fee structure alone can be a bigger obstacle than the ingredient list. It's a fixed cost that has to be paid before a single bottle sells, which is part of why the Korean sunscreen brands that do reach the US tend to be larger companies that can absorb it, or brands that reformulate a US-specific version built entirely from FDA-approved filters rather than importing the Korean formula as-is.
Tariffs Made an Already Hard Market Harder
Import costs are a separate issue from sunscreen authorization. CBP’s 2025 implementation fact sheet dates the worldwide suspension of duty-free de minimis treatment to August 29, 2025. Its temporary postal-duty options should not be read as a permanent “15% or $80” charge for every Korean parcel. Check the current carrier and customs terms for the shipment you are considering.
Korea Isn't Waiting for the US to Catch Up
MFDS proposed adding phenylene bis-diphenyltriazine in January 2026. The March 18, 2026 amendment subsequently added it at a 5% ceiling, subject to an inhalation restriction. The proposal date and the date of the final amendment are different; our Korean filter-list guide gives the Korean names and limits. MFDS Notice 2026-19 is the current source used here.
What This Means If You're Buying From the US Right Now
- For a direct order from abroad, compare the landed total: product, shipping, duties and carrier charges. Do not use a 2025 postal-duty example as a current quotation.
- Bemotrizinol entering the monograph does not establish that a particular Korean sunscreen is available or compliant in the US.
- Because the FDA's approved-filter list is shorter than Korea's, a Korean brand's US-market version may already use different active ingredients than the identical product sold in Korea — worth checking the ingredient list rather than assuming the two are interchangeable. The labels differ too — PA+++ and Broad Spectrum measure UVA protection in different ways.
- https://www.federalregister.gov/documents/2026/06/10/2026-11578/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-counter-human-use
- https://dermapproved.com/blog/why-you-cant-buy-korean-sunscreen-in-a-us-store/
- https://international-and-comparative-law-review.law.miami.edu/blocking-sunblock-regulatory-barriers-to-korean-sunscreens-in-the-united-states/
- https://www.provisionfda.com/post/%ED%95%9C%EA%B5%AD-%EC%9E%90%EC%99%B8%EC%84%A0%EC%B0%A8%EB%8B%A8%EC%A0%9C-%EB%AF%B8%EA%B5%AD-%EC%88%98%EC%B6%9C-%EC%9E%A5%EB%B2%BD-otc-%EB%93%B1%EB%A1%9D-%EC%95%9E%EC%97%90-%EC%9C%84%EA%B8%B0
- https://www.basf.com/us/en/media/news-releases/2026/06/P-US-26-27
- https://www.koreaherald.com/article/10827034
- https://www.npr.org/2025/09/01/nx-s1-5519724/korean-skincare-industry-expected-to-be-hit-hard-by-end-of-de-minimus-exemption
- https://cosmorning.com/news/article.html?no=51974
Correction, October 14, 2026: the de minimis suspension date is August 29, 2025, and the Korean filter list follows MFDS Notice 2026-19 of March 18, 2026. Regulatory timing and import-duty claims have been narrowed. CBP implementation fact sheet · FDA sunscreen regulatory Q&A · MFDS current cosmetic-safety annex
Comments
Post a Comment